With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too. The company is shifting current R&D chief Moncef Slaoui to the top of the new-and-larger vaccines business, and emerging markets head Abbas Hussain will take over the pharma business, overseeing U.S. chief Dierdre Connelly. Report